Compare VRE & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRE | HROW |
|---|---|---|
| Founded | 1949 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1994 | N/A |
| Metric | VRE | HROW |
|---|---|---|
| Price | $15.05 | $41.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $18.25 | ★ $68.86 |
| AVG Volume (30 Days) | 663.9K | ★ 716.4K |
| Earning Date | 10-22-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $291,348,000.00 | $250,042,000.00 |
| Revenue This Year | $6.48 | $43.92 |
| Revenue Next Year | N/A | $41.22 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | 6.39 | ★ 47.83 |
| 52 Week Low | $13.69 | $20.85 |
| 52 Week High | $18.47 | $50.72 |
| Indicator | VRE | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 58.85 |
| Support Level | $14.88 | $36.95 |
| Resistance Level | $15.18 | $41.24 |
| Average True Range (ATR) | 0.29 | 2.64 |
| MACD | 0.01 | 0.52 |
| Stochastic Oscillator | 46.20 | 89.48 |
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.